SCI Pharmtech Inc is a Taiwan-based company mainly engaged in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs), API intermediates, and specialty and precision chemicals. The Company's main product categories are APIs, API intermediates, and specialty chemicals. The Company primarily sells its products in Europe, Asia, the Americas, and other domestic and international markets.

Employees

239

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
22/10/26	NT$52.90	-0.94%	49,912
21/10/26	NT$53.40	+1.14%	67,350
20/10/26	NT$52.80	+0.76%	107,817
19/10/26	NT$52.40	-2.06%	233,913
16/10/26	NT$53.50	+0.19%	42,792

End-of-day quote Taiwan S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SCI Pharmtech, Inc.

Company calendar

End-of-day quote Taiwan S.E. 22/10/2026			5-day change	1st Jan Change
52.90 ^TWD	-0.94%		-3.82%	+8.62%

08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	6.32B 194M 173M 160M 145M 272M 18.36B 276M 1.92B 758M 9.62B 728M 712M 30.48B	P/E 2024	20.3x	P/E 2025	54.2x
Enterprise Value	7.23B 222M 198M 183M 166M 311M 21.01B 316M 2.2B 867M 11.01B 833M 815M 34.87B	EV / Sales 2024	7.3x	EV / Sales 2025	5.01x
Free-Float	54.76%	Yield 2024	1.66%	Yield 2025	1.54%

08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-05	SCI Pharmtech, Inc. Proposes Dividend Distribution for the Period from January 1, 2025 to December 31, 2025	CI
11-07	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/08/25	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
05/06/25	SCI Pharmtech, Inc. Announces Cash Dividend, Payable on August 5, 2025	CI
26/05/25	SCI Pharmtech, Inc. Announces Changes to its Board, Effective May 26, 2025	CI
08/05/25	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/03/25	Sci Pharmtech, Inc. Declares Dividend for Period from January 01, 2024 to December 31, 2024	CI
10/03/25	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/01/25	Sci Pharmtech, Inc. Announces Cash Dividend Payment	CI
20/12/24	Sci Pharmtech, Inc. Announces Appointment of Members of the Sustainable Development Committee	CI

29/06/22	SCI Pharmtech : Notice of appointment of general manager of the Board of Directors.	PU
29/06/22	SCI Pharmtech : Notice of the re-election of chairman of the Board of Directors.	PU
21/06/22	SCI Pharmtech : List of the Company's elected directors.	PU
21/06/22	SCI Pharmtech : Notice of the resolutions of 2022 general shareholders' meeting.	PU
21/06/22	SCI Pharmtech : Notice of re-election of functional committees' members	PU

SCI Pharmtech, Inc. Stock

Stocks

4119

TW0004119003

Pharmaceuticals

Valuation: SCI Pharmtech, Inc.

Chart: SCI Pharmtech, Inc.

Latest news: SCI Pharmtech, Inc.

Press Releases: SCI Pharmtech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: SCI Pharmtech, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 day	-0.94%
1 week	-3.82%
Current month	-4.68%
1 month	-7.68%
3 months	+9.30%
6 months	+10.09%
Current year	+8.62%

1 week	51.7	54
1 month	51.7	58.3
Current year	39.6	60.7
1 year	39.6	60.7
3 years	39.6	100.5
5 years	39.6	119.56
10 years	39.6	119.56

Manager	Title	Age	Since
Wei Chun Weng CEO	Chief Executive Officer	64	-
Wen Chen Yang DFI	Director of Finance/CFO	-	01/01/2003
Wen Chih Chou PRN	Corporate Officer/Principal	-	01/09/2010

Director	Title	Age	Since
Wei Chun Weng CHM	Chairman	64	17/12/2001
Hsiang Li Chen BRD	Director/Board Member	61	17/12/2001
Wen Chih Chou BRD	Director/Board Member	-	01/09/2010

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCI PHARMTECH, INC.	-0.94%	-3.82%	-9.26%	-40.56%	197M
ELI LILLY AND COMPANY	+2.83%	+4.58%	+61.12%	+127.00%	1,133B
JOHNSON & JOHNSON	+4.20%	+6.02%	+39.18%	+77.38%	621B
ABBVIE INC.	-0.11%	+0.35%	+24.37%	+96.50%	503B
ROCHE HOLDING AG	+0.03%	+3.27%	+39.79%	+65.06%	379B
MERCK & CO., INC.	-1.06%	+1.97%	+68.99%	+43.25%	370B
NOVARTIS AG	+1.58%	+2.37%	+22.91%	+52.52%	292B
ASTRAZENECA PLC	+2.90%	+2.22%	+3.51%	+28.51%	262B
AMGEN INC.	+2.37%	+3.31%	+51.49%	+64.21%	237B
GILEAD SCIENCES, INC.	+2.11%	-0.31%	+29.17%	+102.28%	190B
Average	+1.35%	+2.78%	+33.12%	+61.62%	398.82B
Weighted average by Cap.	+1.86%	+3.73%	+43.08%	+84.92%

	2024	2025
Net sales	1.52B 46.72M 41.7M 38.47M 34.95M 65.57M 4.43B 66.58M 463M 183M 2.32B 175M 172M 7.35B	1.34B 41.2M 36.78M 33.93M 30.83M 57.83M 3.9B 58.72M 409M 161M 2.04B 155M 151M 6.48B
Net income	535M 16.39M 14.63M 13.5M 12.27M 23.01M 1.55B 23.36M 163M 64.07M 814M 61.54M 60.22M 2.58B	107M 3.29M 2.94M 2.71M 2.46M 4.62M 312M 4.69M 32.66M 12.87M 163M 12.36M 12.09M 518M
Net Debt	298M 9.13M 8.15M 7.52M 6.83M 12.81M 864M 13.01M 90.53M 35.66M 453M 34.26M 33.52M 1.43B	912M 27.98M 24.97M 23.04M 20.93M 39.27M 2.65B 39.87M 278M 109M 1.39B 105M 103M 4.4B